Last reviewed · How we verify
CTA018 cream
CTA018 cream is a topical corticosteroid used to treat inflammatory skin conditions.
CTA018 cream is a topical corticosteroid used to treat inflammatory skin conditions. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | CTA018 cream |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
CTA018 cream works by reducing inflammation and suppressing the immune system's response in the skin. This is achieved through the inhibition of phospholipase A2, a key enzyme involved in the inflammatory process. By reducing inflammation, CTA018 cream helps to alleviate symptoms associated with various skin conditions.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Skin atrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTA018 cream CI brief — competitive landscape report
- CTA018 cream updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI